Free Republic 2nd Qtr 2025 Fundraising Target: $81,000 Receipts & Pledges to-date: $79,241
97%  
Woo hoo!! And we're now over 97%!! Thank you all very much!! God bless.

Keyword: tenecteplase

Brevity: Headers | « Text »
  • Transition to newer clot-busting drug improves patient outcomes, lowers cost in treating ischemic stroke (Tenecteplase)

    09/25/2022 9:45:06 PM PDT · by ConservativeMind · 4 replies
    Medical Xpress / University of Texas at Austin / Stroke ^ | Sept. 23, 2022 | Steven Warach, M.D. et al
    A newer-generation clot-busting drug called tenecteplase outperforms the traditional treatment for ischemic strokes in several key areas, including better health outcomes and lower costs, according to a study. Both tenecteplase and alteplase are federally approved for use in dissolving clots in blocked heart arteries. But the newer drug tenecteplase is also being used by clinicians, off-label, to treat ischemic strokes, because clinical trials in stroke suggest that it may be at least as good as alteplase and it is easier to administer. Tenecteplase is administered by a single five- to 10-second intravenous injection. The researchers compared its performance with the...
  • Researchers make a significant breakthrough in the treatment of stroke

    06/30/2022 6:46:44 AM PDT · by ConservativeMind · 15 replies
    Medical Xpress / University of Calgary / The Lancet ^ | June 29, 2022 | Bijoy K Menon et al
    In the largest clinical stroke trial ever run in Canada, researchers have shown Tenecteplase (TNK), a safe, well tolerated drug, commonly used as a clot buster for heart attacks, is an effective treatment for acute ischemic stroke. "It is truly an important finding that I share with my colleagues from coast to coast. Through this collaboration these findings could revolutionize stroke treatment throughout the world," says Dr. Bijoy Menon, MD. "Tenecteplase is known to be an effective clot dissolving drug. It is very easy to administer which makes it a game changer when seconds count to save brain cells," Based...